

Molecules 2007, 12, 1092-1100

molecules

ISSN 1420-3049

© 2007 by MDPI

www.mdpi.org/molecules

Full Paper

Biotransformations of Imbricatolic Acid by *Aspergillus niger* and *Rhizopus nigricans* Cultures

Guillermo Schmeda-Hirschmann^{1,*}, Carlos Aranda^{1,2}, Marcela Kurina³, Jaime A. Rodríguez⁴ and Cristina Theoduloz⁴

¹ Laboratorio de Química de Productos Naturales, Instituto de Química de Recursos Naturales, Universidad de Talca, Casilla 747, Talca, Chile

² Current address: Centro de Investigación y Desarrollo de Recursos y Ambientes Costeros, Universidad de Los Lagos, Casilla 557, Puerto Montt, Chile

³ INTEQUI-CONICET, Laboratorio de Química Orgánica, Universidad Nacional de San Luis, Chacabuco y Pedernera 5700, San Luis, Argentina

⁴ Depto. de Ciencias Básicas Biomédicas, Facultad de Ciencias de la Salud, Universidad de Talca, Casilla 747, Talca, Chile

* Author to whom correspondence should be addressed; E-mail: schmeda@utalca.cl; Tel: (+ 56) 71 200288; Fax: (+ 56) 71 200448

Received: 20 April 2007; in revised form: 18 May 2007 / Accepted: 19 May 2007 / Published: 21 May 2007

Abstract: Microbial transformation of imbricatolic acid (**1**) by *Aspergillus niger* afforded 1 α -hydroxyimbricatolic acid (**2**), while transformation with *Rhizopus nigricans* yielded 15-hydroxy-8,17-epoxylabdan-19-oic acid (**3**). When the diterpene **1** was added to a *Cunninghamella echinulata* culture, the main products were the microbial metabolites mycophenolic acid (**4**) and its 3-hydroxy derivative **5**. All the structures were elucidated by spectroscopic methods. The cytotoxicity of these compounds towards human lung fibroblasts and AGS cells was assessed. While **4** and **5** showed low cytotoxicity, with IC₅₀ values > 1000 μ M against AGS cells and fibroblasts, 1 α -hydroxyimbricatolic acid (**2**) presented moderate toxicity towards these targets, with IC₅₀ values of 307 and 631 μ M, respectively. The structure of **2** is presented for the first time.

Keywords: *Aspergillus niger*, *Rhizopus nigricans*, imbricatolic acid, biotransformation, diterpene, *Cunninghamella echinulata*, mycophenolic acid.

Introduction

The diterpene imbricatolic acid (**1**) is one of the main constituents of the resin from the large tree *Araucaria araucana* (Mol.) Koch. The resin, as well as imbricatolic acid, have been recently shown to display gastroprotective effects in induced gastric lesion models in animals [1, 2]. The gastroprotective effect of several semisynthetic derivatives of imbricatolic acid was assessed, but so far none of them contained hydroxy functions in the A ring.


Recent studies have reported the successful use of microorganisms for bioconversion of diterpenes. They include the biotransformation of stemodine by *Rhizopus oryzae* [3], the transformation of isosteviol by *Aspergillus niger*, *Glomerella cingulata* and *Mortierella elongata* [4], transformation of baccatin and 1 β -hydroxybaccatin I with *Aspergillus niger* [5], microbial transformation of a pimarane derivative with *Gibberella fujikuroi* [6], of dehydroabietanol and teideadiol by *Mucor plumbeus* [7], stemodin and several *Stemodia* diterpenes with *Aspergillus niger* [8], *Mucor plumbeus* and *Whetzelinia sclerotiorum* [9].

The aim of the present work was to obtain new hydroxylated derivatives of imbricatolic acid by means of microbial transformation using *Aspergillus niger*, *Cunninghamella echinulata* and *Rhizopus nigricans*.

Results and Discussion

Microbial transformation of imbricatolic acid (**1**) by *Aspergillus niger* afforded a main compound, identified as 1 α -hydroxyimbricatolic acid (**2**), while *Rhizopus nigricans* transformed imbricatolic acid to the epoxy derivative **3**. From the *Cunninghamella echinulata* culture, the main compounds isolated were microbial metabolites, identified as mycophenolic acid (**4**) and its 3-hydroxy derivative **5** (Figure 1). The structures of the known compounds were determined by 1D- and 2D-NMR techniques and confirmed by comparing the physical and spectroscopic/spectrometric data with those from the literature (NMR and MS).

Figure 1. Structures of compounds **1-5**.



The molecular formula of **2** proved to be C₂₀H₃₄O₄ from HREIMS, DEPT and ¹³C-NMR data. The ¹H-NMR spectrum of compound **2** was close to that of **1**, differing mainly by the presence of a broad singlet at δ_{H} 3.85 indicating a OH group, instead of a methylene group in the A ring. In the ¹³C-NMR

spectrum of **2**, eight methylene sp^3 C atoms and an oxygenated methine (δ_C 71.20 d) were observed, instead of the nine methylene sp^3 C atoms seen for imbricatolic acid. The position of the hydroxy function followed from the signal multiplicity and the HMBC correlations. Clear correlations between the H signal at δ 3.85 and C-5 (δ_C 48.55) and C-3 (δ_C 30.70) helped position the OH group at C-1. The H-20 methyl group at δ_H 0.59 also presented a clear HMBC correlation with the C at δ 71.20, supporting the proposed structure. The stereochemistry of the OH function was deduced from the coupling constants which are about 7.7 Hz for the β -hydroxy function while the α -isomer signal appeared as a broad singlet with very small coupling constants (< 1 Hz) [7, 10]. The NMR spectral data of compound **2** are summarized in the Table 1.

Table 1. 1H - and ^{13}C -NMR data of compound **2** (400 and 100 MHz, respectively, $CDCl_3$).

Position	δ_H (J in Hz)	δ_C , mult.
	H	C
1	3.85, br s	71.20, CH
2	1.60, 2.21, m	27.50, CH_2
3	1.94, 1.56, m	30.70, CH_2
4	-	44.00, qC
5	1.82, m	48.55, CH
6	1.87-2.00, m	25.81, CH_2
7	1.89, 2.36, m	38.39, CH_2
8	-	148.62, qC
9	2.21, m	48.34, CH
10	-	44.00, qC
11	1.50, 1.31, m	19.58, CH_2
12	1.15, 1.37, m	35.18, CH_2
13	1.62, m	29.14, CH
14	1.70, 1.29, m	38.81, CH_2
15	3.66, 3.72, m	61.13, CH_2
16	0.88, d (6.6)	20.55, CH_3
17	4.53 s, 4.86 s	106.96, CH_2
18	1.25, s	28.71, CH_3
19	-	183.41, qC
20	0.59, s	13.24, CH_3

Among the several recently reported diterpene biotransformations by *A. niger* [9, 11, 12], only in the bioconversion of isoesteviol, in which the $1\alpha,7\alpha$ -dihydroxy derivative is obtained, was the 1α position hydroxylated [13]. Related compounds with an additional OH function include 3,15-dihydroxy-8(17)-labden-19-oic acid from *Juniperus thurifera* [14, 15], the 6,15-dihydroxyderivative from *Viburnum suspensum* [16] and 7α -hydroxy-8(17)labdene-15,18-dioic acid from *Haplopappus pulchellus* [17]. A 7β -hydroxy labdane derivative was described from *Baccharis pedunculata* [18] while other products were obtained from *Eupatorium salvia* [19]. Labdane derivatives with a 6-

hydroxy function were isolated from *Viburnum suspensum* [16] while 3-hydroxy labdanes were obtained from *Haplopappus chrysanthemifolius* [20]. *Beauveria bassiana* ATCC 7159 was able to hydroxylate the stemodane and stemarane diterpenes stemodin and stemodinone, isolated from the Jamaican plant *Stemodia maritima*. The microorganisms yielded C-18 hydroxylated products of stemodin and stemodinone while stemarin was oxidized at C-1 to the corresponding β -configured alcohol as well as to the C-19 carboxylic acid [21]. *Cunninghamella echinulata* var. *elegans* hydroxylated stemodin to its 7 α -hydroxy, 7 β -hydroxy and 3 β -hydroxy derivatives. Using this microorganism, stemarin was hydroxylated at the 6 α position with oxidation of the C-19 methyl group to a carboxylic acid. *Phanerochaete chrysosporium* was able to hydroxylate stemodin to its 7 β -hydroxy as well as to the 3 β -hydroxy and 11 β -hydroxyderivatives and to hydroxylate stemodinone at C-19 [22]. These reports clearly illustrate the potential of microbial transformations to give selective oxidation products of diterpenoids.

Mycophenolic acid (**4**) has been reported as an immunosuppressive compound [23] and to present promising activity in the treatment of immune-mediated renal diseases [24]. The immunosuppressive and antitumor activities of mycophenolic acid have been recently reviewed [25]. Other biological activities reported for this compound include antifungal, antibacterial and antiviral effects [26]. To the best of our knowledge, this is the first report of mycophenolic acid production by *Cunninghamella* species. Until now the compound was reported only from cultures of *Byssoschlamys nivea* [27] and mainly from several *Penicillium* species, such as *P. brevi-compactum* [28], *P. roqueforti* [29], *P. roqueforti* var. *carneum* [30], *P. bialowiezense*, *P. chrysogenum* [31], *P. raciborkii* [27], *P. stoloniferum* and other *Penicillium* spp. [32]. On the other hand, 3-hydroxymycophenolic acid (**5**) was obtained as a microbial transformation product of mycophenolic acid [33, 34]. The total synthesis of mycophenolic acid has been reported [26].

Compound **2** presented moderate toxicity towards AGS cells and fibroblasts, with IC₅₀ values of 307 and 631 μ M, respectively. Compound **1** presented cytotoxicity IC₅₀ values of 134 and 280 μ M towards AGS cells and fibroblasts, respectively [2]. The cytotoxicity of the derivative **3** (IC₅₀ values) was previously reported as 288 and 305 μ M towards AGS cells and fibroblasts, respectively [2]. Mycophenolic acid (**4**) and its derivative **5** showed low cytotoxicity with IC₅₀ values > 1000 μ M against AGS cells and fibroblasts.

Experimental

General

Melting points were determined on a Koffler hot stage apparatus (Electrothermal 9100) and are uncorrected. Optical rotations were obtained on a Jasco DIP 370 polarimeter, and IR spectra were recorded on a Nicolet Nexus FT-IR instrument. The NMR spectra were recorded in CDCl₃ on a Bruker Avance 400 NMR spectrometer at 400 MHz for ¹H and 100 MHz for ¹³C, respectively. MS spectra were measured in a Varian unit at 70 eV. Silica gel 60 (Merck, 63-200 μ m particle size) was used for column chromatography; precoated Silica gel plates (Merck, Kieselgel 60 F₂₅₄, 0.25 mm) were used for TLC analysis. TLC spots were visualized by spraying the chromatograms with *p*-anisaldehyde-ethanol-acetic acid-H₂SO₄ (2:170:20:10 v/v) and heating at 110 °C for 3 min. Imbricatolic acid (15-

hydroxylabd-8(17)-en-19-oic acid, **1**) was isolated from *Araucaria araucana* resin as previously reported and recrystallized as colorless crystals, mp 102-105 °C [1, 2].

Microorganisms

The microorganisms used were either from the American Type Culture Collection (ATCC): *Aspergillus niger* ATCC 16404, *Cunninghamella echinulata* ATCC 8688a or the Micoteca de la Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Argentina: *Rhizopus nigricans* UBA 6.

Screening scale experiments

Liquid Czapek medium (30 mL) held in 125 mL Erlenmeyer flasks was inoculated with a spore suspension in a first fermentation stage. Stage I cultures were incubated on a rotatory shaker at 250 rpm and 28 °C ± 2 °C for 48 h. The second fermentation stage was initiated by transferring the inoculum from the Stage I culture in a final volume of 10%. After 48 h incubation, substrate **1** (10 mg) dissolved in dimethylformamide was added in each flask. Samples (5 mL of incubation media) were withdrawn every 12, 24 and 48 h, partitioned with EtOAc (2 mL) and analyzed by TLC. Three experiments with two repetitions each were carried out for every fungal agent. Blank assays without substrate and without fungi were carried out.

Preparative scale experiments and product isolation

Aspergillus niger ATCC 16404 culture.

First fermentation stage was performed as described for the screening experiments. In Stage II the substrate at 200 mg L⁻¹ was added to each of ten 5 L-Erlenmeyer flasks containing 48 h old culture (1 L). After 15 days, the culture was separated into culture medium and mycelium by filtration. Extraction of the culture filtrates with EtOAc (3 x 500 mL each) after acidification with HCl to pH 5, afforded 800 mg of EtOAc-solubles. Chromatography of the crude extract on silica gel (100 g, column length 42 cm, internal diameter 1.8 cm) with a CHCl₃-acetone gradient afforded 56 fractions, pooled into nine groups according to the TLC patterns. From the fraction pools 1-2, some 85 mg imbricatolic acid (**1**) was recovered, while the pooled fraction 6 (70 mg), yielded 30 mg of *1-α,15-dihydroxylabd-8(17)-en-19-oic acid* (*1-α-hydroxyimbricatolic acid* (**2**) as colorless crystals; mp 179-181 °C; $[\alpha]_D^{20} + 56.77^\circ$ (c = 0.303, MeOH); IR (KBr) ν_{\max} 3441, 2942, 2928, 1687, 1461, 1197, 1060, 1029, 895 cm⁻¹; for NMR data, see Table 1; EIMS m/z 338 [M]⁺ (17), 320 (46), 275 (74), 234 (48), 219 (52), 201 (29), 189 (38), 182 (41), 173 (100), 169 (63), 159 (39), 137 (73), 133 (84), 123 (86), 197 (87), 95 (95), 81 (94), 55 (96); HREIMS m/z 338.485 (calcd. for C₂₀H₃₄O₄, 338.485).

Cunninghamella echinulata ATCC 8688a culture.

First fermentation stage was performed as described for the screening experiments. In Stage II the substrate (200 mg L^{-1}) was added to each of 12 5 L-Erlenmeyer flasks containing 48 h culture (1 L). After 14 days, the culture was separated into culture medium and mycelium by filtration. Extraction of the culture filtrates with EtOAc (3 x 500 mL each), after acidification with HCl to pH 5, afforded 4.9 g of EtOAc-solubles. Chromatography of the crude extract on 400 g silica gel with a petroleum ether (PE)-ethyl acetate (EtOAc) gradient afforded some 65 fractions of ca. 70 mL each. Fractions 1-9 contained no compounds of interest and were discarded. Fractions 10-18 yielded some 80 mg of imbricatolic acid (**1**), while fractions 26-28 afforded 500 mg of mycophenolic acid (**4**) [26] and the pooled fractions 29-46 contained 10.5 mg of 3-hydroxymycophenolic acid (**5**) [33, 34]. The spectroscopic of the isolated compounds were in agreement with the structures and with published data.

Rhizopus nigricans UBA6 culture.

First fermentation stage was performed as was described for the screening experiments. In Stage II the substrate (200 mg L^{-1}) was added to each ten 5 L-Erlenmeyer flasks containing 48 h culture (1 L). After 5 days, the culture was separated into culture medium and mycelium by filtration. Extraction of the culture filtrates with EtOAc (3 x 500 mL) after acidification with HCl to pH 5, afforded 680 mg of EtOAc-solubles. This EtOAc extract was chromatographed on 40 g silica gel with a PE, PE-EtOAc, EtOAc and EtOAc-MeOH gradient. Fractions 1 (PE, 100 mL), 2-3 (PE-EtOAc 9:1, 200 mL) and 4 (PE-EtOAc 8:2, 100 mL) did not contain any compounds of interest and were discarded. Fractions 5 and 6 (PE-EtOAc 7:3 and 1:1, 100 mL each) contained 120 mg of imbricatolic acid (**1**). Fractions 7-8 eluted with EtOAc (200 mL) and 9-10 (EtOAc-MeOH 9:1, 200 mL) afforded a mixture of imbricatolic acid (**1**) and a second, more polar compound which gave a red-violet spot with anisaldehyde-sulphuric acid reagent. Preparative TLC of the combined fractions 7-10 (silica gel, PE-EtOAc 1:1) afforded 60 mg of imbricatolic acid (**1**) and 30 mg of 15-hydroxy-8,17-epoxylabdan-19-oic acid (**3**) [2].

MRC-5 cell culture

The cytotoxic effect of the assayed compounds, expressed as cell viability, was assessed on a permanent fibroblast cell line derived from human lung (MRC-5) (ATCC CCL-171). MRC-5 fibroblasts were grown as monolayers in minimum essential Eagle medium (MEM), with Earle's salts, L-glutamine (2 mM) and sodium bicarbonate (2.2 gL^{-1}), supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS), penicillin (100 IU mL^{-1}) and streptomycin ($100 \text{ } \mu\text{g mL}^{-1}$) in a humidified incubator with 5% CO_2 in air at 37 °C. Cell passage was maintained between 10 and 16. The medium was changed every 2 days.

AGS cell culture

The cytotoxic effect of the assayed compounds, expressed as cell viability, was assessed on a permanent human gastric epithelial cell line (AGS) (ATCC CRL-1739). The AGS cells were grown as

monolayers in Ham F-12 medium containing *L*-glutamine (1 mM) and sodium bicarbonate (1.5 gL^{-1}), supplemented with 10% (v/v) heat-inactivated FBS, penicillin (100 IUmL^{-1}) and streptomycin ($100 \text{ } \mu\text{g mL}^{-1}$) in a humidified incubator with 5% CO_2 in air at 37 °C. The cell passage was maintained between 42 and 48. The medium was changed every 2 days.

Cytotoxicity assay

Confluent cultures of MRC-5 as well as AGS cells were treated with medium containing the diterpene derivatives at concentrations ranging from 0 up to 1000 μM . The products were first dissolved in DMSO and then in the corresponding culture medium supplemented with 2% FBS. The final content of DMSO in the test medium and controls was 1% (v/v). Cells were exposed for 24 h to the test medium with or without the compound (control). Each concentration was tested in quadruplicate together with the control and repeated three times in separate experiments. At the end of the incubation, the neutral red uptake (NR) assay was carried out [35]. To calculate the IC_{50} values (concentration that produces a 50% inhibitory effect on the evaluated parameter) the results were transformed to percentage of controls and the IC_{50} values were graphically obtained from the dose-response curves.

Acknowledgements

Financial support by FONDECYT, Grant N° 1030583 and the Programa de Productos Bioactivos, University of Talca is gratefully acknowledged. Carlos Aranda thanks the Programa en Biotecnología Silvoagrícola for a postdoctoral grant.

References

1. Schmeda-Hirschmann, G.; Astudillo, L.; Rodríguez, J.A.; Theoduloz, C.; Yáñez, T. Gastroprotective effect of the Mapuche crude drug *Araucaria araucana* resin and its main constituents. *J. Ethnopharmacol.* **2005**, *101*, 271-276.
2. Schmeda-Hirschmann, G.; Astudillo, L.; Sepúlveda, B.; Rodríguez, J.A.; Theoduloz, C.; Yáñez, T.; Palenzuela, J.A. Gastroprotective effect and cytotoxicity of natural and semisynthetic labdane diterpenes from *Araucaria araucana*. *Z. Naturforsch. C* **2005**, *60*, 511-522.
3. Martin, G.D.; Reynolds, W.F.; Reese, P.B. Stemodane skeletal rearrangement: chemistry and microbial transformation. *Phytochemistry* **2005**, *66*, 901-909.
4. Akihisa, T.; Hamasaki, Y.; Tokuda, H.; Ukiya, M.; Kimura, Y.; Nishino, H. Microbial transformation of isosteviol and inhibitory effects on Epstein-Barr virus activation of the transformation products. *J. Nat. Prod.* **2004**, *67*, 407-410.
5. Shen, Y.C.; Lo, K.L.; Lin, C.L.; Chakraborty, R. Microbial transformation of baccatin VI and 1beta-hydroxy baccatin I by *Aspergillus niger*. *Bioorg. Med. Chem. Lett.* **2003**, *13*, 4493-4496.
6. Fraga, B.M.; González, P.; Hernández, M.G.; Chamy, M.C.; Garbarino, J.A. Microbial transformation of 18-hydroxy-9,13-epi-ent-pimara-7,15-diene by *Gibberella fujikuroi*. *J. Nat. Prod.* **2003**, *66*, 392-397.

7. Fraga, B.M.; Hernández, M.G.; Artega, J.M.; Suárez, S. The microbiological transformation of the diterpenes dehydroabietanol and teideadiol by *Mucor plumbeus*. *Phytochemistry* **2003**, *63*, 663-668.
8. Chen, A.R.M.; Reese, P.B. Biotransformation of terpenes from *Stemodia maritima* by *Aspergillus niger* ATCC 9142. *Phytochemistry* **2002**, *59*, 57-62.
9. Chen, A.R.M.; Ruddock, P.L.D.; Lamm, A.S.; Reynolds, W.F.; Reese, P.B. Stemodane and stemarane diterpenoid hydroxylation by *Mucor plumbeus* and *Whetzelinia sclerotiorum*. *Phytochemistry* **2005**, *66*, 1898-1902.
10. Gouiric, S.C.; Feresin, G.E.; Tapia, A.A.; Rossomando, P.C.; Schmeda-Hirschmann, G.; Bustos, D.A. 1 β ,7 β -Dihydroxydehydroabietic acid, a new biotransformation product of dehydroabietic acid by *Aspergillus niger*. *World J. Microbiol. Biotechnol.* **2004**, *20*, 281-284.
11. Schmeda-Hirschmann, G.; Astudillo, L.; Palenzuela, J.A. Biotransformation of solidagenone by *Alternaria alternata*, *Aspergillus niger* and *Curvularia lunata* cultures. *World J. Microbiol. Biotechnol.* **2004**, *20*, 93-97.
12. Orden, A.A.; Cifuentes, D.A.; Borkowski, E.J.; Tonn, C.E.; Kurina, M. Stereo- and regioselective hydroxylation of grindelic acid derivatives by *Aspergillus niger*. *Nat. Prod. Res.* **2005**, *19*, 625-631.
13. de Oliveira, B.H.; dos Santos, M.C.; Leal, P.C. Biotransformation of the diterpenoid, isosteviol, by *Aspergillus niger*, *Penicillium chrysogenum* and *Rhizopus arrhizus*. *Phytochemistry* **1999**, *51*, 737-741.
14. San Feliciano, A.; Miguel del Corral, J.M.; Lopez, J.L.; de Pascual-Teresa, B. Labdane acids from polar extracts of *Juniperus thurifera*. *Phytochemistry* **1992**, *31*, 1719-1722.
15. San Feliciano, A.; Miguel del Corral, J.M.; Lopez, J.L.; de Pascual-Teresa, B. Further diterpene acids from *Juniperus thurifera*. *Phytochemistry* **1993**, *33*, 1165-1167.
16. Iwagawa, T.; Yaguchi, S.; Hase, T.; Okubo, T.; Kim, M. Diterpene glucosides from *Viburnum suspensum*. *Phytochemistry* **1993**, *32*, 1515-1518.
17. Zdero, C.; Bohlmann, F.; Niemeyer, H. Friedolabdanes and other constituents from Chilean *Haplopappus* species. *Phytochemistry* **1991**, *30*, 3669-3677.
18. Jakupovic, J.; Schuster, A.; Wasshausen, D.C. Acetylenes and labdanes from *Baccharis pedunculata*. *Phytochemistry* **1991**, *30*, 2785-2787.
19. González, G.A.; Bermejo, B.J.; Diaz, J.G.; Rodríguez Perez, E.M.; Yanes, A.C.; Rauter, P.; Pozo, J. Diterpenes and other constituents of *Eupatorium salvia*. *Phytochemistry* **1990**, *29*, 321-323.
20. Faini, F.; Labbe, F.; Torres, R.; Delle Monache, F.; Delle Monache, G. Diterpenes from *Haplopappus chrysanthemifolius*. *Phytochemistry* **1999**, *52*, 1547-1550.
21. Buchanan, G.O.; Reese, P.B. Biotransformation of diterpenes and diterpene derivatives by *Beauveria bassiana* ATCC 7159. *Phytochemistry* **2001**, *56*, 141-151.
22. Lamm, A.S.; Reynolds, W.F.; Reese, P.B. Bioconversion of *Stemodia maritima* diterpenes and derivatives by *Cunninghamella echinulata* var. *elegans* and *Phanerochaete chrysosporium*. *Phytochemistry* **2006**, *67*, 1088-1093.
23. Nelson, P.H.; Eugui, E.; Wang, C.C.; Allison, A.C. Synthesis and immunosuppressive activity of some side-chain variants of mycophenolic acid. *J. Med. Chem.* **1990**, *33*, 833-838.

24. Dal Canton, A.; Amore, A.; Barbano, G.; Coppo, R.; Emma, F.; Grandaliano, G.; Klersy, C.; Perfumo, F.; Rizzoni, G.; Schena, F.P.; Sepe, V. One-year angiotensin-converting enzyme inhibition plus mycophenolate mofetil immunosuppression in the course of early IgA nephropathy: a multicenter, randomised, controlled study. *J. Nephrol.* **2005**, *18*, 136-140.
25. Casadio, F.; Croci, S.; D'Errico Grigioni, A.; Corti, B.; Grigioni, W.F.; Landuzzi, L.; Lollini, P.L. Renal transplantation toward the definition of immunosuppressive regimens with antitumor activity. *Transplant. P.* **2005**, *37*, 2144-2147.
26. Covarrubias-Zúñiga, A.; González-Lucas, A.; Domínguez, M.M. Total synthesis of mycophenolic acid. *Tetrahedron* **2003**, *59*, 1989-1994.
27. Puel, O.; Tadríst, S.; Galtier, P.; Oswald, I.P.; Delaforge, M. *Byssochlamys nivea* as a source of mycophenolic acid. *Appl. Environm. Microbiol.* **2005**, *71*, 550-553.
28. Doerfler, D.L.; Bartman, C.D.; Campbell, I.M. Mycophenolic acid production by *Penicillium brevicompactum* in two media. *Can. J. Microbiol.* **1979**, *25*, 940-943.
29. Schneewis, I.; Meyer, K.; Hormansdorfer, S.; Bauer, J. Mycophenolic acid in silage. *Appl. Environm. Microbiol.* **2000**, *66*, 3639-3641.
30. Boysen, M.; Skouboe, P.; Frisvad, J.; Rossen, L. Reclassification of the *Penicillium roqueforti* group into three species on the basis of molecular genetic and biochemical profiles. *Microbiology* **1996**, *142*, 541-549.
31. Frisvad, J.C.; Smedsgaard, J.; Larsen, T.O.; Samson, R.A. Mycotoxins, drugs and other extrolites produced by species in *Penicillium* subgenus *Penicillium*. *Stud. Mycol.* **2004**, *49*, 201-241.
32. Dictionary of Natural Products on CD-ROM. Chapman and Hall/CRC: Boca Raton, FL, USA **2006**.
33. Jekkel, A.; Barta, I.; Kónya, A.; Süt, J.; Boros, S.; Horváth, G.; Ambrus, G. Microbiological transformation of mycophenolic acid. *J. Mol. Catal. B: Enzym.* **2001**, *11*, 423-426.
34. Jekkel, A.; Barta, I.; Boros, S.; Süt, J.; Horváth, G.; Szabó, Z.; Ambrus, G. Microbial transformation of mycophenolic acid Part II. *J. Mol. Catal. B: Enzym.* **2002**, *19-20*, 209-214.
35. Rodríguez, J.A.; Haun, M. Cytotoxicity of *trans*-dehydrocrotonin from *Croton cajucara* (Euphorbiaceae) on V79 cells and rat hepatocytes. *Planta Med.* **1999**, *65*, 522-526.

Sample Availability: Samples of compounds **1** and **3** are available from the authors.